Skip to main content
SpringerLink
Log in

Fakt oder (Science-)Fiction?

Risikofaktoren beim CS-I-Seminom

  • Fortbildung
  • Published:
Uro-News Aims and scope

Bei Hodentumoren im klinischen Stadium I wird immer seltener mit adjuvanter Chemo- oder Strahlentherapie behandelt. Manchmal kann dies jedoch nach wie vor sinnvoll sein. Während des Rezidivrisiko bei Nichtseminomen relativ gut abschätzbar ist, bedarf die Situation bei Seminomen einer differenzierten Betrachtung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Zengerling F et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol. 2018; 36: 448–58

    Article  Google Scholar 

  2. Hoskin P et al. Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol. 1986; 4: 1031–6

    Article  CAS  Google Scholar 

  3. Kollmannsberger C et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015; 33: 51–7

    Article  Google Scholar 

  4. Ruf CG et al. Adjuvant carboplatin therapy in patients with clinical stage 1 testicular seminoma: is long-term morbidity increased? J Cancer Res Clin Oncol. 2019; 145: 2335–42

    Article  CAS  Google Scholar 

  5. Patel HD et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol. 2017; 35: 606.e1–606.e7

    Article  Google Scholar 

  6. Cohn-Cedermark G et al. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology. 2015; 3: 102–10

    Article  CAS  Google Scholar 

  7. Oliver RT et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366: 293–300

    Article  CAS  Google Scholar 

  8. Dieckmann KP et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016; 142: 1599–607

    Article  CAS  Google Scholar 

  9. Kollmannsberger C et al. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol. 2011; 22: 808–14

    Article  CAS  Google Scholar 

  10. Lewinshtein D et al. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int. 2012; 109: 706–12

    Article  Google Scholar 

  11. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur „Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens“ Langversion 1.0 — September 2018 AWMF-Registernummer: 043/049OL

  12. Albers P et al. EAU Guidelines on Testicular Cancer 2019. https://uroweb.org/guideline/testicular-cancer/ (abgerufen am 22.10.2019)

  13. Tandstad T et al. Treatment of seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016; 27: 1299–304

    Article  CAS  Google Scholar 

  14. Mortensen MS et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014; 66: 1172–8

    Article  Google Scholar 

  15. Warde P et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol. 1997; 157: 1705–9

    Article  CAS  Google Scholar 

  16. Chung P et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer medicine. 2015; 4: 155–60

    Article  Google Scholar 

  17. Soper MS et al. Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort. Am J Clin Oncol. 2014; 37: 356–9

    Article  CAS  Google Scholar 

  18. Aparicio J et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014; 25: 2173–8

    Article  CAS  Google Scholar 

  19. Yu HY et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol. 2009; 27: 4327–32

    Article  Google Scholar 

  20. Dieckmann KP et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019; 37: 1412–23

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin Vivantes Klinikum Am Urban, Universitätsklinik Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland

    Friedemann Zengerling

Authors
  1. Friedemann Zengerling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Friedemann Zengerling.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zengerling, F. Risikofaktoren beim CS-I-Seminom. Uro-News 23, 32–35 (2019). https://doi.org/10.1007/s00092-019-3015-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-019-3015-2

Search

Navigation